US adult obesity rate declines as weight-loss drug use surges in 2025, but diabetes prevalence reaches new high.
Diddy begins serving 50-month sentence at Fort Dix, seeks rehabilitation and family visits.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
US adult obesity rate declines as weight-loss drug use surges in 2025, but diabetes prevalence reaches new high.
Diddy begins serving 50-month sentence at Fort Dix, seeks rehabilitation and family visits.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.